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Adjuvant use of chemotherapy has established efficacy in
several solid human tumours – breast, colon and lung cancers
being among the most frequent. The role of adjuvant treat-
ment – either locoregionally or systemically after local treat-
ment, allowing a complete resection of the primary tumour
and locoregional lymph nodes – is to improve cure rates.
The goal of adjuvant chemotherapy is to eradicate micro-
metastases that may already be established but are undetect-
able as well as to destroy possible circulating tumour cells.
The benefit, however, is hypothetical, and patients are gener-
ally selected on the basis of the pTNM staging obtained at sur-
gery. One has to keep in mind that most of the patients who
will be disease-free at 5 years have already been cured by sur-
gery. The benefit of adjuvant chemotherapy is always limited
in terms of magnitude to low percentages, and the risk/bene-
fit ratio for a given patient is low. In addition, adjuvant che-
motherapy has its own toxicity that may be acute but also
long-lasting even after termination. Taking these consider-
ations into account, the use of chemotherapy and the choice
of cytotoxic agents should be based on properly conducted
clinical trials, with a well-defined population and a follow-
up long enough to assure a real benefit with time. Data from
efficacy in metastatic settings should not simply be applied to
adjuvant use without results of randomised trials in this situ-
ation and a proven level of evidence. Tumour cell biology
shows that a given tumour evolves with time, and that meta-
static disease is quite a different disease from the adjuvant
setting.
The purpose of this Educational Lecture is:
• To review the data on adjuvant chemotherapy for NSCLC.
• To analyse how the concept has evolved with time.
• To present the results of meta-analysis.
• To provide an update on the most recent trials.
• To examine the impact on special populations.
• To look at possible prognostic/predictive biomarkers.
• To provide recommendations for routine practice.2. The first signal of a possible effect of
adjuvant chemotherapy in resected NSCLC
During the last 4 decades of the 20th century, numerous trials
of various sample sizes and chemotherapy combinations
have been performed in various settings worldwide. Despite
an effort to accrue about 10,000 patients in 50 clinical trials,
none of them individually has been convincing enough to
establish adjuvant chemotherapy as a standard of care. In
1995, the Non-Small Cell Lung Cancer Collaborative Group
under the joint auspices of the Medical Research Council
(MRC) in the United Kingdom, Institut Gustave Roussy in
France and Istituto Mario Negri in Italy published a meta-
analysis looking at the impact of adjuvant chemotherapy in
resected non-small-cell lung cancer (NSCLC) [1]. They re-
viewed updated data on individual patients from randomised
trials performed between 1965 and 1991. All types of treat-
ment were analysed, including adjuvant chemotherapy, radi-
ation therapy and advanced disease. Among these trials, 14 –
including a total of 4357 patients – were performed in the
postoperative setting and compared surgery to surgery + che-
motherapy. The drugs used were heterogeneous, as were the
doses, and overall no benefit on overall survival was shown.
The analysis was refined on the basis of the heterogeneity be-
tween categories of regimen used, and that was statistically
significant. Therefore, chemotherapy regimens were grouped
into three categories: (1) long-term alkylating agents, (2) other
drugs, and (3) cisplatin-based. No heterogeneity was found
within each category, and a separate meta-analysis was per-
formed for each of the three groups. The hazard ratios (HRs)
of death showed differences among the groups, already sug-
gesting that the choice of chemotherapy was important: (1)
long-term alkylating agents: HR 1.15 (1.04–2.20), P 0.005; (2)
other drugs: HR 0.89 (0.72–1.11) P 0.30; and (3) cisplatin-based:
HR 0.87 (0.74–1.02) P 0.08.
These initial results showed a highly significant detrimen-
tal effect of long-term alkylating agents, with a 15% increase
in the risk of death from alkylating agents. On the contrary, in
the cisplatin-containing regimen group, the benefit, although3; fax: +33
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translating into an improved 5% survival at 5 years; however,
this survival benefit was not significant, and in practice cis-
platin-based adjuvant chemotherapy is not a standard of care
for resected NSCLC at this time.
Based on the results of the meta-analysis, further random-
ised trials were performed taking advantage of the ‘‘signal’’
seen earlier with cisplatin-based chemotherapy.3. Evolution of the concept of adjuvant
chemotherapy for resected NSCLC
After the initial meta-analysis of adjuvant chemotherapy in
resected NSCLC by the Non-Small Cell Lung Cancer Collabora-
tive Group, additional randomised trials were performed and
meta-analysed by Hotta and other Japanese investigators [2].
This second meta-analysis included 11 trials with a total of
5716 patients, performed in Japan but also in the rest of the
world. Among these randomised trials six had UFT, an oral
fluoropyrimidinewidely used in Japan, either as a single agent
or in combination with cisplatin. The remaining five were
more in agreement with what is used in the western world,
including etoposide, mitomycin C, vindesine, vinorelbine or
vinblastine in combination with cisplatin. Sample sizes were
sometime small, trials having 100 patients or fewer. Most of
these trials individually showed no significant benefit on the
5-year survival rate, but overall the meta-analysis obtained
an HR of 0.87 at a significant P value of 0.001. When only
the cisplatin-containing regimens were considered, the HR
was 0.89 with a P value of 0.012. In Japanese patients treated
in UFT single-agent trials, the risk of death was reduced by
20% (HR 0.799, P value 0.015).
Additional trials based on platinum-containing regimens
have also been performed in the western world and will be
summarised individually below.3.1. IALT
The International Adjuvant Lung Cancer Trial (IALT) Collabo-
rative Group [3,4] conducted a pragmatic randomised trial,
started in 1995, evaluating the impact of a cisplatin-based
chemotherapy in resected NSCLC (stages I–III according to
the 1986 AJCC classification). The experimental arm offered
three or four cycles of various cisplatin-containing regimens
to be compared by observation. Companion drugs associated
with cisplatin included one of four drugs (vindesine, vinblas-
tine, vinorelbine or etoposide), the dose of cisplatin was left to
the discretion of each centre (ranging from 80 to 120 mg/m2),
as was the number of cycles (three or four) or the use of adju-
vant radiotherapy. A total of 14 regimens were therefore pos-
sible. The trial was planned for 3300 patients, but it
discontinued early with 1867 patients because of low accrual
due to the emergence and recent results of neoadjuvant che-
motherapy. The most frequent chemotherapy regimens used
(in 76% of patients) were cisplatin–etoposide and cisplatin–
vinorelbine. Additional radiation was delivered in 20–25% of
patients. The patient population included 36% stage I (10%
IA), 24% stage II and 40% stage III. At the date of publication
[3], after a median follow-up of 56 months, a significant over-all survival benefit was seen with a 14% reduction in the risk
of death and a P value of 0.03, translating into a 4.1% survival
benefit at 5 years. No subgroup analysis was reported, but G.
Strauss [4] in a separate paper concluded that only stage III
patients were benefiting from adjuvant chemotherapy.
The results of IALTwere later updated in 2010 [5]. The ini-
tial benefit seen with a median follow-up of 56 months was
not confirmed when more events were observed after a med-
ian of 7.5 years of follow-up. The HR for overall survival
moved up from 0.86 to 0.91, with a no-longer-significant P va-
lue of 0.10. The analysis of the cause of death showed a slight
increase in non-cancer-related death in the chemotherapy
arm, possibly reflecting long-term adverse effects of adjuvant
chemotherapy (HR 1.36, P value 0.06), the incidence of local
recurrences or distant metastases remaining lower in the
adjuvant chemotherapy population. This emphasises the
need for a sufficiently long follow-up for adjuvant trials.
3.2. Big Lung Trial
The Big Lung Trial [5,6] was a pragmatic, UK-based trial to
evaluate the impact of cisplatin-containing chemotherapy in
NSCLC in all settings: early, locally advanced and metastatic.
In the adjuvant situation, cisplatin could be combined
with several drugs, including mitomycin–ifosfamide (MIC),
mitomycin–vinblastine (MVP), vindesine (CV) or vinorelbine
(NP). The trial started in 1995 and stopped in 2001. It accrued
in the surgical setting only 381 patients out of 1394 planned. It
is therefore difficult to draw conclusions from such a small
sample size. With a median follow-up of 35 months the HR
of 1.02 (P value 0.90) showed no benefit at all.
3.3. ALPI
The Adjuvant Lung Project Italy (ALPI) [6] along with the Euro-
pean Organisation for Research and Treatment of Cancer
(EORTC) performed an adjuvant chemotherapy trial in re-
sected stages I, II and III (UICC/AJCC 1986) NSCLC. Surgery fol-
lowed by adjuvant chemotherapy with mitomycin, vindesine
and cisplatin (MVP) was compared with surgery alone. Three
cycles of chemotherapy were planned after randomisation.
The study accrued 1209 patients between January 1994 and
January 1999. After a median follow-up of 65 months, the
overall survival HR was 0.96 (P = 0.589), showing no benefit
from adjuvant chemotherapy. This negative trial had several
weaknesses: 108 patients from a single centre were excluded
from the analysis, only 69% of randomised patients received
the three planned cycles of chemotherapy and half of them
required dose reduction. The toxicity of MVP was prohibitive
with an excess of toxic death during the first year. However,
even though the study was negative, the 3.4% overall survival
benefit at 5 years was not that different from that of the IALT
(4.1%).
3.4. CALGB 9633
In the United States, CALGB 9633 [7,8] evaluated the use of
three or four cycles of paclitaxel–carboplatin in the adjuvant
setting for resected stage IB only (T2N0 TNM 6 classification).
This study planned to accrue 500 patients starting in Septem-
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presented first at ASCO 2004 [7] with 34 months of follow-
up, and full mature data were published in 2008 [8] with a
median follow-up of 74 months. At the initial ASCO 2004 pre-
sentation, the outcome was in favour of adjuvant paclitaxel–
carboplatin, with an overall survival HR of 0.62 (P = 0.028) and
a 4-year survival rate of 71% versus 59% in the control arm.
This was the first study to demonstrate a benefit in early stage
IB. However, the updated publication with a much longer fol-
low-up did not confirm the initial, preliminary results. With
time and more events, the overall survival HR went up to
0.83 (P = 0.12), a 2% improvement on the 5 year-survival rate.
Similarly, as seen in the IALT discussed above, in CALGB
9633 the benefit of adjuvant faded with time and emphasised
the need for prolonged follow-up to establish the proof of
benefit in adjuvant setting.
Interestingly enough, a subgroup exploratory analysis was
performed in CALGB 9633 according to tumour size P or
<4 cm [8]. In the updated analysis with a 74 month follow-
up the overall survival in stage IB was not improved in the in-
tent-to-treat population, but an overall survival benefit was
seen for patients with a tumour P4 cm with an HR of
death = 0.69 and a P value = 0.043, a median overall survival
of 99 months compared with 77 months in the surgery only
arm. On disease-free survival the magnitude of the benefit
was similar for tumoursP4 cm. These data support the adju-
vant use of paclitaxel–carboplatin in patients with resected
stage pIB P4 cm NSCLC.
3.5. NCIC JBR 10
From July 1994 to April 2001, the National Cancer Institute of
the Canada Clinical Trials Group (NCIC-CTG) [9,10] accrued
482 NSCLC patients in the JBR-10 phase III randomised trial
of adjuvant cisplatin–vinorelbine versus surgery alone for R0
resected stages pIB (45%) and pII (except T3N0, TNM 6 classi-
fication). Patients were randomised to receive four cycles of
cisplatin–vinorelbine over 16 weeks in the chemotherapy
arm versus observation in the control arm. The results were
published after median follow-up of 5.1 years [9] and updated
after 9.3 years.
Overall survival was improved after 5 years of follow-up
with an HR of death of 0.69, P = 0.009, reflecting a 15% benefit
at 5 years (69 versus 54%) and medians of 94 versus
73 months. Similarly, disease-free survival was extended in
the chemotherapy group (HR 0.60, P < 0.001). The updated sur-
vival data after 9.3 years showed that the benefit was pre-
served with time with an HR of death = 0.78 (P = 0.04) [10].
Subgroup analysis according to stage IB versus II did not show
a statistically significant benefit in stage IB. The benefit was
restricted to stage II (HR 0.59, P = 0.004). In the updated anal-
ysis with 9.3 years of follow-up, similar findings were re-
ported. Based on the tumour size effect reported in CALGB
9633, this parameter was examined in JBR-10 with a cut-off
value of 4 cm in stage IB. Similarly, in JBR-10 a difference
was noted, with a potential detrimental effect of adjuvant cis-
platin–vinorelbine in stage IB <4 cm (HR 1.73, P = 0.56) and a
potential benefit in tumours P4 cm (HR 0.66, P = 0.133).
In an attempt to find a predictive biomarker of efficacy, the
RAS mutational status (including H, N and KRAS) was evalu-ated in 451/482 patients. Ras mutational status was not asso-
ciated with a differential effect of chemotherapy.
Chemotherapy compliance in JBR-10 showed that 45% of
patients randomised to cisplatin–vinorelbine received the
planned four cycles, 55% three cycles and 64% two cycles.
The median number of delivered cycles was three. The most
frequent adverse event was neutropenia. Dose of vinorelbine
was reduced from 30 to 25 mg/m2 weekly after 18 patients
were treated initially.
The JBR-10 trial established the benefit of adjuvant cis-
platin–vinorelbine (the first third-generation drug combined
with cisplatin) in stage II R0 resected NSCLC, and possibly in
stage IB P4 cm.
3.6. ANITA 1
ANITA (Adjuvant Navelbine International Trialists Associa-
tion) [11] is an international randomised phase III trial evalu-
ating on overall survival the benefit of 4 cycles of cisplatin–
vinorelbine in R0 resected p stages IB (T2N0), II and IIIA
NSCLC (TNM 6). From December 1994 to December 2000, a to-
tal of 840 patients were accrued, with 407 randomised to che-
motherapy. The use of adjuvant radiation therapy – after
surgery in the control arm or after chemotherapy in the
experimental arm – was allowed, neither randomised nor
mandatory but left to the decision of the investigators.
With a median follow-up of 70 months, the primary overall
survival end-point was met on the intent-to-treat population
(HR of death 0.79, P = 0.013), a benefit of 8.6% at 5 years con-
firmed at 7 years. Relapse-free survival was also significantly
improved (HR of relapse 0.76, P = 0.002). No difference was
seen with the surgery alone arm in stage IB (62% versus 64%
survival at 5 years). The benefit was actually restricted to
stages II and IIIA. In stage II, the 5-year survival rates were
52% versus 39% in the chemotherapy arm versus control
arm respectively (HR of death 0.71), in stage IIIA 42% versus
26% (HR of death 0.69). These results do not allow a definitive
conclusion, however, since the test of interaction was not sig-
nificant and no P values were calculated. The impact of the N
stage was reported independently of T stage: for pN0 patients
median overall survival was 99.6 versus 95.5 months in the
control arm and chemotherapy arm respectively. In patients
with pN1 disease, median overall survivals were respectively
31.2 versus 65.7 months in favour of adjuvant chemotherapy
and 20 versus 32.6 months in patients with pN2 stages. No
conclusion can be reached from adjuvant radiation since its
use was not randomised, but it showed a potential detrimen-
tal effect in pN1 disease after adjuvant chemotherapy and a
benefit in pN2 disease [12]. This will have to be confirmed in
a clinical trial, presently ongoing, and will be discussed
elsewhere.
Chemotherapy compliance, similar to the results of JBR10,
showed that 73% of patients received two cycles, 61% three
cycles and 50% the planned four cycles, with a relative dose
intensity of 59% for vinorelbine and 89% for cisplatin, reflect-
ing the toxicity of the regimen with 85% grade 3–4 neutrope-
nia and 9% febrile neutropenia.
The ANITA trial established the value of adjuvant cis-
platin–vinorelbine (the first third-generation drug combined
with cisplatin) in stage II and IIIA R0 resected NSCLC.
134 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 3 1 –1 3 6Within the LACE, a subgroup analysiswasperformedonpa-
tientswho received the vinorelbine–cisplatin chemotherapy in
theadjuvantsetting fromJBR10,ANITA, IALTandBLT, fora total
of 1888 patients [13]. Overall, the survival benefit was 8.9% at
5 years (HR of death 0.80, P < 0.001). Stagewas a significant pre-
dictor of efficacy on 5-year survival: 14.7% in stage III, 11.6% in
stage II andonly 1.8% in stage I. These resultswere significantly
superior to other cisplatin-based combination chemotherapy
regimens used in the LACE meta-analysis (P = 0.04).4. The impact of adjuvant chemotherapy on
special populations
4.1. Adjuvant chemotherapy in elderly patients
The use of adjuvant chemotherapy may be an issue in clinical
practice since the life expectancy is increasing and medical
progress allows resection in the elderly population, including
for NSCLC.
The JBR.10 investigators have reported the results of their
trial on elderly patients, with a cut-off age set at P65 years,
and comparedwith patients <65 years old [14]. The two groups
differed significantly in terms of histology (more adenocarci-
noma in the younger group) and performance status (more
PS = 0 in the younger group). The benefit of adjuvant cis-
platin–vinorelbine on overall survival, reported for the overall
population, was also seen in the elderly,P65 years old (HR of
death 0.61, P = 0.04). Elderly patients significantly received few-
er doses of cisplatin and vinorelbine, and the dose intensity
was significantly reduced as well. No differences in toxicity
were observed. According to this analysis, adjuvant cisplatin–
vinorelbine seems feasible in patientsP65 years old.
Addressing the same question of the effect of age on cis-
platin-based adjuvant chemotherapy, the LACE group com-
pared the overall survival of three groups according to age
(<65, 65–69, >70 years old) [15]. The HRs of death were 0.86 for
<65-year-olds, 1.01 for the mid category (65–69 years old), and
0.90 in the oldest patients (>70). The test for trend was not sig-
nificant and the LACE concluded that ‘‘chemotherapy should
not be withheld from the elderly purely on the basis of age’’.
Similar to JBR.10, lowerdoses of cisplatinand fewer cycleswere
delivered in the elderly. No differences in toxicity were
observed.
Based on these two reports, adjuvant cisplatin-based che-
motherapy seems feasible in elderly patients and provides a
survival benefit with acceptable tolerance.
Age is not the only parameter to consider in practice,
however, and patients from clinical trials with strict inclu-
sion criteria are not always reflecting the general practice
population. Decisions should also take into account perfor-
mance status, comorbidities, compliance issues and patient
willingness.
4.2. Japanese population
In Japan, as opposed to the Western world or other Asian
countries, fluoropyrimidines are widely used to treat NSCLC.
UFT, an oral fluoropyrimidine – either as a single agent or in
combination with cisplatin – has been evaluated in random-ised clinical trials for the adjuvant treatment of resected
NSCLC versus surgery alone. Those trials have been meta-
analysed. In the meta-analysis by Hamada et al. [16], individ-
ual patient data were collected. Among nine trials, six com-
pared surgery versus surgery + UFT; two had a third arm
with cisplatin-containing chemotherapy, but the patients for
the third arm were not meta-analysed. Most of the patients
presented with adenocarcinoma and early stage I disease.
They were treated for a period of 1–2 years with oral UFT. In
this selected population of 2003 patients, the use of UFT post-
operatively showed a significant benefit at 5 and 7 years com-
paredwith surgery alone (respectively +4.3% and +7%) with an
HR of death of 0.74 (P = 0.001).
Another Japanese meta-analysis – based on published data
of adjuvant trials performed worldwide since 1995 – included
11 trials among which six were UFT-based [2]. A separate
analysis of the UFT-containing regimen was provided. Most
of the trials were not statistically significant due to small
sample sizes. The use of UFT as a single agent on 1751 pa-
tients showed a significant benefit with an HR of death of
0.799 (P = 0.015). In the UFT-containing regimen trials the
use of UFTwas prolonged to 1 or 2 years.
The benefit of UFT in adjuvant chemotherapy is so far lim-
ited to Japanese patients since the drug is not used for this
indication outside Japan.5. Predictive biomarkers of chemotherapy
efficacy in the adjuvant setting
The benefit of adjuvant chemotherapy in NSCLC is still recent.
Very few trials have looked at predictive biomarkers that
would allow better patient selection. The available data are
from retrospective studies with the limitations associated
with such an approach.
5.1. ERCC 1
In 2006, the IALT group reported that the level of expression of
ERCC 1 (excision repair cross-complementation group 1) by
immunohistochemistry was both predictive for the efficacy
of cisplatin-based chemotherapy on survival and prognostic
[17]. In a subsequent study from the LACE biology, looking
at the four protein isoforms of ERCC 1 in the entire population
of the LACE group, with additional antibodies mapping ERCC
1, the predictive effect of ERCC 1 was not validated [18]. Based
on these results, ERCC 1 cannot be recommended at the pres-
ent time to select patients for adjuvant cisplatin-containing
chemotherapy.
5.2. KRAS
In the JBR10 trial [10], KRAS mutational status was assessed
for its potential value as a predictive factor of resistance to
chemotherapy. No differential benefit on overall survival
was noticed between KRAS wild-type and mutant patients.
However, a trend towards a benefit was observed for dis-
ease-specific survival (DSS) with adjuvant cisplatin–vinorel-
bine in the KRAS wild-type patients (HR of DSS 0.72,
P = 0.06), with no benefit in mutant patients.
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for their KRAS mutational status on codons 12, 13 and 14 [19].
Overall, KRAShasnoprognostic value according to the survival
in the surgery-alone arm. There was also no significant differ-
ence in overall survival according to the KRAS mutational sta-
tus between the control arm and the adjuvant chemotherapy
arm. Looking more specifically at the mutation type, there is
much variability in the effect of adjuvant chemotherapy
among the patients harbouring a codon 12 mutation, none of
them being significant due to the size of the samples. The co-
don 13 mutation was associated with a detrimental effect of
adjuvant chemotherapy (HR of death 5.78, P = 0.002), but this
information would require validation from a larger sample.
At the present time, KRAS should not be used for the deci-
sion for adjuvant chemotherapy in NSCLC.
5.3. Other biomarkers
The LACE Bio group has undertaken an extensive analysis of
biomarkers that could potentially act as predictive factors of
adjuvant chemotherapy efficacy. In addition to ERCC 1 and
KRAS that have been already reported, this search includes
beta-tubuline, mucine, P53, P27, P16, cyclin E, Bax, EGFR
mutation as well as histology and lymphocytic infiltration.
Another approach undertaken by several groups is to look
for a gene signature that would be associated with improved
survival and efficacy of chemotherapy. Several sets of genes
have been identified in retrospective studies, but none so far
has implications in clinical practice.
At the present time, no predictive biomarker has been
identifiedwhich could be used in clinical practice. Much hope,
however, is placed on such tools to better define selected pa-
tients who would benefit from adjuvant chemotherapy.
6. Conclusion
As in other human solid tumours, adjuvant chemotherapy for
resected NSCLC is now part of the standard of care.
It should be offered at all ages in fit patients resected with
stage II and III disease. Stage IB might be discussed, mainly
with tumours of >4 cm in diameter.
Adjuvant chemotherapy in Western countries should be
cisplatin based. Among the companion drugs to be combined
with cisplatin, vinorelbine is the only third-generation drug
that has been evaluated and that has demonstrated durable
long-termefficacy. All the otherdrugs tested – including etopo-
side, vindesine, vinblastine and paclitaxel (combinedwith car-
boplatin) – have finally failed to demonstrate a definitive
efficacy. The other third-generation drugs docetaxel, gemcita-
bine and pemetrexed havenever been evaluated in proper ran-
domised trials with overall survival as the primary endpoint.
Therefore, the only combination to be used in an adjuvant set-
ting for resected NSCLC, on evidence-based medicine, is vino-
relbine–cisplatin. Other compounds – including targeted
agents – with proven efficacy in metastatic settings have not
been evaluated in the adjuvant setting. Anti-EGFR tyrosine ki-
nase inhibitorshave failed todemonstrate abenefit in theadju-
vant setting of EGFR-mutated NSCLC in the JBR 19 randomised
trial. They cannot be recommended for such use.Metastatic stages and early or locally advanced diseases
have different behaviours. It is known that in other tumour
types, such as colon cancer, regimens with similar efficacy
in stage IV do not translate into similar benefit in earlier
stages. Considering the possibility of cure in the majority of
patients with surgery alone, and the limited benefit of adju-
vant chemotherapy in terms of improved 5-year survival, no
added risk should be taken for the patients in a situation
where the risk/benefit ratio is rather small.
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